Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Minnesota Medical Development's Rebound HRD:

This article was originally published in Clinica

Executive Summary

The Rebound HRD hernia repair device developed by Minnesota Medical Development has been granted 510(k) clearance by the US FDA. The Rebound HRD is a self-expanding surgical mesh device composed of Nitinol, designed for the laparoscopic repair and/or reinforcement of both inguinal and ventral hernias. It conforms to the anatomy while providing stability, eliminating the need for anchoring, which, in turn, minimises patient post-op discomfort and the risk of nerve/blood vessel injury. It can also be used for other soft tissue defects where weakness exists and where the support of a non-absorbable material is preferred. The Plymouth, Minnesota company CE-marked the product for sale in the EU in June (see Clinica No 1261, p 22).

You may also be interested in...



Canada Allows Exceptional Drug, Device Imports To Tackle COVID-19 Shortages

Medical products that do not fully comply with Canadian requirements but are manufactured according to comparable standards are being allowed into the country to deal with COVID-19-related shortages.

Canada Allows Exceptional Drug, Device Imports To Tackle COVID-19 Shortages

Medical products that do not fully comply with Canadian requirements but are manufactured according to comparable standards are being allowed into the country to deal with COVID-19-related shortages.

RECOVERY Coronavirus Study ‘Will Attract Global Players To UK’

A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.

Topics

UsernamePublicRestriction

Register

MT049556

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel